BARICITINIB IMPROVES THE SYMPTOMS OF ATOPIC DERMATITIS

摘要

Adding the oral selective Janus kinase (JAK) 1 and 2 inhibitor baricitinib (4mg) to topical corticosteroid (TCS) treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis (AD), a phase III study in JAMA Dermatology has suggested (30 September 2020).